Novel pharmacological targets for the inhibition of inflammation and airway remodeling in asthma
Rahmawati, Siti Farah

DOI:
10.33612/diss.569857035

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2023

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Rahmawati, S. F. (2023). Novel pharmacological targets for the inhibition of inflammation and airway remodeling in asthma. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.
https://doi.org/10.33612/diss.569857035

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 01-10-2023
CHAPTER 4

The pharmacological rationale for targeting IL-17 in asthma

S.F. Rahmawati1,2,4, M. te Velde1,4, H.A.M. Kerstjens3,4, A.S.S. Dömling5, M.R. Groves1, R. Gosens1,4,*

1Department of Molecular Pharmacology, University of Groningen, Groningen, The Netherlands.
2Department of Pharmacology and Clinical Pharmacy, Institut Teknologi Bandung, Bandung, Indonesia.
3Department of Pulmonary Medicine, University of Groningen and University Medical Center Groningen (UMCG), Groningen, The Netherlands.
4Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Centre Groningen (UMCG), Groningen, The Netherlands.
5Department of Drug Design, University of Groningen, Groningen, The Netherlands.
*Corresponding author

Chapter 4 - The pharmacological rationale for targeting IL-17 in asthma

Abstract

Asthma is a respiratory disease that currently affects around 300 million people worldwide and is defined by coughing, shortness of breath, wheezing, mucus-overproduction, chest tightness, and expiratory airflow limitation. Increased levels of IL-17 have been observed in sputum, nasal and bronchial biopsies, and serum of asthma patients compared to healthy controls. Patients with higher levels of IL-17 have a more severe asthma phenotype. Biologics are available for Th2-high asthmatics, but the Th17-high subpopulation has a relatively low response to these treatments, rendering it a rather severe asthma phenotype to treat. Several experimental models suggest that targeting the IL-17 pathway may be beneficial in asthma. Moreover, as increased activation of the Th17/IL-17 axis is correlated with reduced ICS sensitivity, targeting the IL-17 pathway might reverse ICS unresponsiveness. In this review, we present and discuss the current knowledge on the role of IL-17 in asthma and its interaction with the Th2 pathway, focusing on the rationale for therapeutic targeting of the IL-17 pathway.

Keywords: Asthma, interleukin 17, severe asthma, corticosteroid, neutrophilic asthma.

Introduction

Asthma is a respiratory disease that currently affects around 300 million people worldwide and is defined by coughing, shortness of breath, wheezing, mucus-overproduction, chest tightness, and expiratory airflow limitation (1). Asthma treatments are categorized as controller medications (anti-inflammatories alone or in combination with long-acting bronchodilators), reliever medications (bronchodilators), and add-on therapies for patients with severe asthma (1). Asthma that is uncontrolled with a high dose of inhaled corticosteroids (ICS) and second controller (long-acting inhaled b2 agonists, montelukast, and/or theophylline) and/or systemic CS for at least 6 months is defined as severe asthma (2). A comprehensive review about the current understanding of severe asthma and its treatment has been compiled by Israel E. et al (3). The current add-on treatment options for severe asthma are long-acting muscarinic antagonist (LAMA), leukotriene modifier, low dose azithromycin, and low dose oral corticosteroids (OCS), and biologicals such as anti-IgE, anti-IL-5/IL-5R or anti-IL-4R for type 2 severe asthma (1,3).

Asthma is characterized by airway hyperresponsiveness associated with chronic airway inflammation (1). Several types of airway inflammation have been recognized in the pathobiology of asthma, (4,5). Type 2 inflammation is well-studied and characterized by its downstream (GM-CSF, IL-3, IL-4, IL-5, IL-9 and IL-13) and upstream (thymic stromal lymphopoietin (TSLP), IL-25 and IL-33) cytokines. This Th2-high endotype is linked to orchestration of the eosinophil biology and considered as an important type of inflammation in a significant subpopulation of asthmatics (4,notch6). Other mechanisms include Th1 inflammation importantly mediated by the production of interferon-gamma (IFNγ), and Th17 inflammation characterized by IL-17A, IL-17E, IL-17F, and IL-22 cytokine production, that leads to neutrophil activation via IL-8 (7). Both Th2 and Th17 pathways can stimulate airway inflammation, tissue fibrosis and airway hyperresponsiveness (AHR). However, the Th17 dependent inflammation is considered to be less sensitive to steroids, which constitute the primary anti-inflammatory treatment for asthma control (8,9).

Increased levels of IL-17 have been observed in in sputum, nasal and bronchial biopsies, and serum of asthma patients compared to healthy controls (10–14). Moreover, expression is more pronounced in moderate-to-severe than in mild asthmatics (11,14–17). In mild-to-moderate asthmatics, the level of IL-17A in airway submucosal layer was significantly increased, whereas IL-17F was higher in both mild-to-moderate and severe asthma (14). Patients with higher levels of IL-17 are classified as a Th17-high inflammation in asthma. So far, there is no biologic
treatment for Th17 high asthmatics, as opposed to the effective biologics for Th2 high. In fact, Th17-high subpopulation has a relatively low response to Th2 biologics, rendering this a relatively more severe asthma phenotype (11,12,15,16,18,19).

Th17-high asthma is often referred to as neutrophilic asthma. During the onset of asthma, stimulation of the Th17/IL-17A axis leads to the release of neutrophil chemokattractants and their accumulation in the airways stimulates the development of neutrophil-based asthma with increasing severity (15,20). All the above indicates that IL-17 exerts multiple effects in the progression of asthma that differ from the classical and more treatable Th2 types of the disease. As there are no anti-inflammatory treatment options available for Th17 high patients, there is an unmet clinical need for effective therapeutic strategies targeting Th17-driven asthma.

**Molecular control of IL-17 signaling**

The IL-17 cytokine family was first identified in 1995, and consists of six known members: IL-17A – IL-17F, with their corresponding five receptors: IL-17 receptor (IL-17RA) – IL-17RE, wherein IL-17A and IL-17F bind to the same receptor (IL-17RA) (21,22). IL-17 exerts a variety of effects, including the attraction of immune cells and activation of inflammatory signaling in airway structural cells (23,24). Th17 is the primary immune cell responsible for the secretion of IL-17A/F and its regulatory cytokines, IL-21, IL-22, TGF-β, and TNF-α (25). This distinct cell type constitutes a subset of CD4+T cells generated from Tho cells by stimulation with low concentrations of TGF-β, IL-6, or IL-21 (26). Further, Th17 cells are maintained and matured by IL-23 (26,27). When IL-23 binds to the IL-23 receptor (IL-23R) expressed by Th17 cells, it activates Janus kinase 2 (JAK2) which subsequently phosphorylates signal transducer and activator of transcription 3 (STAT3) that enters the cell nucleus to induce transcription of specific target genes (26). This signaling cascade triggers Th17 cells to express IL-17 (26,28). Other types of immune cells that are known as the source of IL-17 including γδ T cells (induced by IL-23, IL-1, retinoic acid, β-glucan, or bacterial products), CD4+ invariant natural killer T (iNKT) cells (induced by IL-23 or glycolipid), lymphoid-tissue inducer (LT)-like cells (induced by IL-23, IL-7, or bacterial product), natural killer (NK) cells (induced by IL-23, retinoic acid, or IL-15), and myeloid cells such as neutrophils (induced by IL-6 and IL-23) (29,30).

The initially defined IL-17R, IL-17RA, is a type I transmembrane protein that consists of an extracellular domain, a transmembrane domain and a cytoplasmic tail (21,25). IL-17RA serves as a co-receptor for IL-17A and IL-17F, the two best-known members of the IL-17 family (22). In humans, IL-17RA gene expression has been identified in B and T lymphocytes, epithelial cells, fibroblasts, smooth muscle cells, macrophages, bone marrow stromal cells, monocytes and vascular endothelial cells (31,32). This might explain the broad influence on IL-17 on the regulation of normal physiological as well as pathological responses (33).

The molecular control of IL-17 signaling is depicted in figure 1. In the canonical pathway, upon binding to the IL-17R, IL-17 recruits Act1 to the receptor via interaction with SEF/IL-17R (SEFIR), a conserved region of the receptor in the cytoplasmic tail (33). Act1 further recruits several TNF receptor associated factors (TRAFs) needed for IL-17 transcriptional and post-transcriptional regulation (33). The mechanism involved in transcription is dependent on inclusion of TRAF6 that activates the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-xB), CCAAT/enhancer binding protein (C/EBP)β, C/EBPδ, and mitogen-activated protein kinase (MAPK) pathways. Recruitment of the TRAF2-TRAF5 complex occurs post-transcriptionally resulting in messenger ribonucleic acid (mRNA) stabilization by stimulating mRNA stabilizing factors and/or by inhibiting mRNA destabilizing factors, thereby maintaining the translation of IL-17 target genes (22,33). The non-canonical IL-17 pathway was recently found to functionally interact with epidermal growth factor receptor (EGFR), fibroblast growth factor 2 (FGF2), NOTCH1, and C-type lectin receptor components (33). In addition, IL-17 is also known to act synergistically with other activators of NF-xB (TNF-α), STAT1 (IFN-γ), STAT6 (IL-13), and SMADs (TGF-β) (33).

The downstream effects of IL-17 signaling activation mainly occur via attracting immune cells, notably neutrophils (26,31,33). The IL-17/IL-17R signaling axis in lung epithelial cells induces the expression of granulocyte-colony stimulating factor (G-CSF) and neutrophil recruiting chemokines, such as C-X-C ligand 1 (CXCL1), CXCL2 and CXCL5 (34). These downstream effects include normal physiological responses, such as host defense regulation and tissue repair, as well as several pathological responses, including development of several types of cancer (carcinoma, adenoma), aggravation of autoimmune diseases (psoriasis, rheumatoid arthritis, ankylosing spondylitis), asthma and COPD (33).
Th17, neutrophil activation, inflammasome, oxidative phosphorylation (OXPHOS) and aging signatures. On the other hand, TAC2 and TAC3 were described as Th2-low clusters, with high ILC1, neutrophil activation, and inflammasome signatures for TAC2, and high ILC3, Th17, OXPHOS and aging signatures for TAC3 respectively (35). Interestingly, eosinophilic inflammation correlates with TAC1 and TAC3, mixed granulocytic inflammation with TAC1 and TAC2, neutrophilic inflammation with TAC2, and a paucigranulocytic condition with TAC3 (35).

An IL-17A gene signature consisting of the 11 most upregulated genes in primary airway epithelial cells, including CXCL13, CSF3, CXCL6, VNN1, SLC26A4, SAA1, SAA2, MTNR1A, TNIP3, and CXCL5, has recently been identified (9). Although the presence of this gene signature has not yet been studied in asthma, this gene signature was further analyzed to evaluate the significance of its level of expression with regards to patients’ clinical characteristics in 2 COPD studies, GLUCOLD and SPIROMICS (9). The IL-17 gene signature was found to be correlated with airway tissue neutrophils, airway tissue macrophages, and sputum neutrophils (9). Interestingly, it was negatively associated with change of forced expiratory volume in 1 s (FEV1) % predicted in all treatment arms and notably in patients receiving corticosteroids (CS), suggesting that the IL-17 gene signature not only represents a potential tool to assess airway disease severity but may also predict CS responsiveness (9).

The Th2 pathway in asthma can be recognized by increased secretion of IL-4, IL-5, and/or IL-13 resulting in eosinophilic inflammation (36). Moreover, the presence of an IL-13-inducible gene signature (i.e., chloride channel, calcium-activated, family member 1 (CLCAt), peristin (POSTN), and serine peptidase inhibitor, clade B (ovalbumin), member 2 (SERPINB2)) in airway epithelial brushings is considered as markers for this endotype (37). In addition to these specific gene signatures, asthma phenotypes can also be predicted by the expression of sputum six gene signature (6GS), which are ALPL, CLC, CP4, CXCR2, DNASel1, and IL13 (38). The 6GS expression can significantly distinguish between eosinophilic asthma (high CLC, CP4, and DNASel1 expressions) versus non-eosinophilic asthma, and between neutrophilic asthma (high IL1B, CXCR2, ALPL expressions) versus non-neutrophilic asthma (38).

Although both Th2 and Th17 pathways are able to stimulate airway inflammation, tissue fibrosis and AHR, only Th2 cell-mediated effects are CS sensitive (8,39). In fact, treatment with CS further elevated the influx of neutrophils in the lung and upregulated IL-17-inducible chemokines, CXCL3 and CXCL5, in a preclinical model of allergen-induced asthma (39). Thus, patients with predominantly Th17-driven airway inflammation are likely less sensitive or even unresponsive to CS treatment.
Interestingly, the Th2 and Th17 pathways have been reported to regulate each other. Several studies showed that IL-13-induced IL-17 downregulation is mediated through the JAK/STAT6-signaling pathway (8, 40–42). In a murine model of asthma, neutralization of the Th2 cytokines IL-4 and IL-13 increased Th17 cell number and neutrophilic inflammation in the lung (8). Accordingly, mice with IL-4R alpha deficiency exhibited elevated levels of IL-17 and decreased eosinophil recruitment into the airways (43). Furthermore, human Th17 cells express the IL-13Rα1 and stimulation with IL-13 prevented IL-17 secretion from these cells (41).

The pharmacological rationale for targeting IL-17 in asthma

The level of IL-17 in the airways is correlated with sputum (9, 12) and bronchial (16) neutrophil counts. The mechanism by which IL-17 regulates neutrophil activities has been increasingly studied over the past decade. It has been demonstrated that interferon-γ (IFN-γ) plus lipopolysaccharide (LPS)-stimulated neutrophils induce the production of CCL2 and CCL20, which bind to CCR2 and CCR6, respectively, on Th17 cells (52). These interactions resulted in Th17 activation which could be effectively inhibited by anti-CCL20 and anti-CCL2 antibodies (52). Moreover, in a mouse model of combined allergic asthma with Haemophilus influenzae infection, Th17 cell differentiation and neutrophil influx into the airway were significantly induced, resulting in allergic neutrophilic asthma features that were steroid-resistant (53, 54). These data suggest that IL-17 might play an important role in neutrophilic asthma associated with airway infection. Indeed, neutrophilic asthmatics have a lower diversity of sputum microbiota compared with eosinophilic asthma, which correlates with airway infection in asthma patients (55). Furthermore, patients with neutrophilic asthma have higher pathogenic bacteria, i.e. Haemophilus and Moraxella taxa, and reduced common airway microorganisms, such as Gemella, Porphyromonas, and Streptococcus taxa, compared to eosinophilic asthma (55).

Conversely, activated Th17 cells affect neutrophils by promoting the production of CXCL8/IL-8, a well-known chemoattractant of neutrophils, in the microenvironment and via granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor-α (TNF-α), and IFN-γ release (52). This suggests reciprocal crosstalk between neutrophils and Th17 cells via these chemokines. However, neutrophils do not express IL-17RC; therefore, they cannot be activated directly by IL-17.
either IL-17A or IL-17F produced by Th17 cells (52). The effect of IL-17 on neutrophils is rather indirect by means of activating structural cells, including airway epithelial cells, fibroblasts, and airway smooth muscle (ASM) cells, to produce the above-mentioned cytokines and chemokines that in turn interact with neutrophils (34,42,43,56–60).

**Disease severity and IL-17**

The prevalence of severe asthma ranges from 3.6% to 6.1% in the total adult population-based asthma cohort, and is associated with an age over 50 years, nasal polyposis, impaired lung function, sensitization to mold, and female gender (51). Asthma that is uncontrolled with a high dose of inhaled corticosteroids (ICS) and second controller (long-acting inhaled b2 agonists, montelukast, and/or theophylline) and/or systemic CS for at least 6 months is defined as severe asthma (2). Uncontrolled asthma is clinically characterized by inadequate symptom control, frequent severe exacerbations, and airflow limitation despite bronchodilator use (2). Airflow obstruction in severe asthma might be due to structural alterations in the airway (airway remodeling) (5). Severe asthmatics have a higher risk of asthma exacerbation and morbidity (3).

The challenging task of targeting severe asthma is further complicated by the complex and diverse pathobiology of asthma. Phenotyping, which integrates biological and clinical characteristics, has been used to categorize asthma into several clusters (2); these represent the range of disease severity from mild-to-moderate asthma with predominantly eosinophilic inflammation to moderate-to-severe asthma with neutrophilic or mixed granulocytic inflammation (3,50,61).

Several studies have reported higher levels of IL-17, notably IL-17A and IL-17F, in sputum, nasal and bronchial biopsies, and blood of patients with severe asthma as compared to those with mild asthma (11,12,15,16,19). In fact, an IL-17 level of 20 pg/ml in serum was identified as an independent risk factor for severe asthma (15). Likewise, histological expression of IL-17F exceeding values of 23 cells/mm² in bronchial and 19 cells/mm² for nasal biopsies could be used to discriminate between mild and severe asthmatics (16). These findings suggest that IL-17 can be considered a biomarker for severe asthma.

The presence of IL-17 in asthma has been demonstrated in several preclinical and clinical studies. IL-17-related cytokine expression was upregulated in nasal and bronchial biopsies of neutrophilic asthmatic patients just prior to an exacerbation, indicating a possible role of IL-17F in frequent exacerbators (16). This was in line with observations by Östling et al (2019), who showed that IL-17-high asthmatics were at risk of frequent exacerbations (44).

More severe AHR is another hallmark feature of severe asthma. In a study that measured AHR by quantifying the response to methacholine in asthmatic children, AHR was reported to be positively correlated with serum IL-17A as well as the number of Th17 cells and the Th17/Treg ratio in PBMCs (13). In a mixed Th2/Th17 mouse model of steroid-insensitive asthma, IL-17A was shown to be an independent contributor to AHR (62). In addition, the presence of Th17 cells in mice resulted in increased AHR that could not be resolved with dexamethasone treatment, whereas inhibition of IL-17A was effective (39,40). These studies also showed that the effect of the IL-17 pathway on AHR were associated with the number of neutrophils, suggesting regulation by the IL-17-neutrophil axis (39,40).

Furthermore, an association of IL-17 with lung function and steroid sensitivity is evident. Thus, the FEV1 value of asthmatics negatively correlated with the expression of IL-17F in bronchial and nasal biopsies as well as the number of Th17 cells in serum, serum IL-17A and the Th17/Treg ratio (13,16).

**Effects of IL-17 on airway remodeling**

Airway remodeling is an important feature of severe asthma and contributes to lung function reduction and obstruction of airflow (63). It is characterized by goblet cell hyperplasia, elevated submucosal extracellular matrix deposition, thickening of reticular basement membrane (RBM), ASM cell hyperplasia and tissue hypertrophy, and changes in the bronchial microvasculature (64–66).

Changes in airway epithelium are considered hallmark features of airway remodeling. These changes include epithelial to mesenchymal transition (EMT), which is a phenotypic conversion of epithelial cells characterized by cell disaggregation as well as reduced epithelial (e.g., E-cadherin) and increased mesenchymal (e.g., vimentin, α-SMA) marker expression (67). IL-17A has been shown to induce EMT of primary murine bronchial epithelial cells by inhibiting E-cadherin expression and stimulating vimentin expression via NF-κB activation (58). IL-17A has also been shown to affect mucus production by airway epithelium. Exposure to IL-17A increased IL-13-stimulated expression of the goblet cell hyperplasia marker, chloride channel, calcium activated 3 (CLCA3), in mouse lungs via enhanced IL-13-induced STAT6 signaling (68). In line with these findings, a study using a mouse asthma model of Th17 inflammation showed a correlation between IL-17A expression and goblet cell number (69). Furthermore, IL-17A induced MUC5AC gene and protein expression...
through NF-κB activation in differentiated primary human bronchial epithelial cell cultured in air liquid interface (ALI) and a human bronchial epithelial cell line (HBE1) (70). These studies strongly suggest that IL-17A elevates mucus production. Another epithelial response to IL-17 is related to extracellular matrix (ECM) production. Hyperreactivity of STAT3 in T-lymphocytes resulted in expansion of Th17 cells in murine lung parenchyma and overexpression of matrix metalloproteinase-9 (MMP9) (71). MMP9 stimulates degradation of ECM proteins, including collagen and laminin, which is consistent with airway epithelial remodeling.

IL-17A also exerts its influence on fibroblast function. Primary mouse lung fibroblasts stimulated with IL-17A in vitro showed elevated TGF-β1 secretion and pro-collagen1a2 (proCol1a2) expression (69). The TGF-β1 secretion by fibroblasts was further increased after co-stimulation with IL17A and wingless-type MMTV integration site family, member 5A (Wnts5a), suggesting the involvement of a IL-17A/Wnts5a/TGF-β1-axis mediating the effects of lung fibroblasts on airway remodeling (69). In agreement with these studies on murine fibroblasts, supernatant of IL-17A-exposed primary human parenchymal fibroblast culture increased collagen synthesis and TGF-β1 secretion in primary human lung fibroblasts (72). Moreover, fibroblast proliferation induced by these supernatants was attenuated by anti-TGF-β1, indicating that IL-17A-stimulated fibroblast activation was mediated by autocrine TGF-β1 expression (72).

In another study, normal human lung fibroblasts expressed IL-17RA and proliferated in response to 1 and 10 ng/ml IL-17A (73). Stimulation with IL-17A also increased α-SMA expression, indicating fibroblast-to-myofibroblast transdifferentiation. Moreover, when cultured on soft (polyacrylamide) gels, IL-17A-stimulated ECM deposition (collagen type 1 and fibronectin) in primary human lung fibroblasts (73). These responses were carried out via NF-κB signaling and inhibition of JAK2, but not JAK1/3, prevented these fibrogenic responses (73). Interestingly, IL-23, a known regulator of IL-17 expression, also employs JAK2 in its mechanism (26). Furthermore, IL-17A upregulated fibronectin and collagen-III protein expression in primary normal human parenchymal fibroblasts but not in normal human bronchial fibroblasts, indicating that IL-17A effects on ECM production are dependent on fibroblast phenotype (60).

ASM tissue hypertrophy, a result of cellular hyperplasia and/or hypertrophy, represents a prominent feature of airway remodeling (64). In one study, a mouse model of mixed Th2/Th17 asthma was developed by intranasally transferring allergen-pulse LPS with ATP-activated dendritic cells. In this model, IL-17A production was correlated with α-SMA, a marker for mesenchymal cells and ASM thickness (69). The expression of Th17-related cytokines receptors, such as IL-17RA, IL-17RC and IL-22R1, has been detected in primary human ASM cells (74). The corresponding cytokines, IL-17A, IL-17F and IL-22, were shown to promote ASM cells migration in a dose-dependent manner, which could be inhibited by blockade of these receptors, implying receptor-dependent effects (74). Furthermore, the IL-17A and IL-17F responses could be partially prevented by a p38 MAPK inhibitor, whereas IL-22-stimulated effects were attenuated by NF-κB inhibition (74). IL-17A, IL-17F, and IL-22 induce proliferation of primary human ASM cells as well (75). These effects were mediated by ERK 1/2 MAPK for IL-17A and IL-17F, and by both ERK 1/2 MAPK and NF-κB signaling for IL-22. These cytokines were also shown to decrease apoptosis and promote cell survival; in addition to effects on migration and proliferation, this could potentially contribute to ASM mass thickening (75).

**IL-17 and steroid sensitivity in asthma**

ICS constitute the cornerstone controller therapy in the treatment of asthma of all severities (1). ICS exert their anti-inflammatory effect via transcriptional and post-transcriptional mechanisms (76). ICS transcriptional mechanisms interfere with pro-inflammatory and anti-inflammatory genes that are induced by inflammation. Upon binding to glucocorticoid receptors (GRs), and predominantly GRα, ICS form a heterodimer complex that translocates into the nucleus and binds to a DNA recognition site known as glucocorticoid response element (GRE) in the steroid-responsive-gene promoter regions (76,77). This induces transcriptional co-activator molecules, such as cyclic AMP element binding protein (CREB), to acetylate core histones resulting in activation of anti-inflammatory gene transcription (76,77). On the other hand, ICS suppress transcription of inflammatory genes via interaction with pro-inflammatory transcription factors, such as NF-κB and activator protein 1 (AP-1), which reverses histone acetylation and prevents pro-inflammatory gene transcription (76). ICS also inhibit the MAPK pathway via MKP-1 stimulation resulting in the blockade of the expression of several pro-inflammatory genes. Post-transcriptionally, ICS promote degradation of pro-inflammatory mRNA that was previously stabilized by certain pro-inflammatory cytokines, thereby alleviating inflammation (76).

With a more advanced understanding of asthma pathophysiology, particularly with regards to ICS responsiveness, there is a growing body of research on reduced ICS sensitivity in asthma. Failure of ICS to adequately inhibit inflammatory molecular and/or clinical features can be caused by several mechanisms, including GR modification, increased GRβ expression, increased pro-inflammatory transcription factors (e.g., NF-κB and AP-1), immune mechanisms (e.g., elevated Th17 activity,
decreased Treg activity), and defective histone acetylation and deacetylation (76,78). Detailed reviews on the mechanisms of reduced ICS sensitivity in asthma are available (76,78).

IL-17 has been associated with reduced steroid sensitivity in inflammatory diseases, including asthma. An in vitro study showed that Th17 cells differentiated from naive CD4+ T cells from antigen-specific TCR-transgenic mice are unresponsive to dexamethasone and continue to produce IL-17A and IL-22 despite successful translocation of GRs into the nucleus (39). Transfer of these Th17 cells into mice challenged with ovalbumin was sufficient to induce increased CXC chemokine secretion, neutrophil infiltration, and AHR, all of which were less responsive to DEX treatment (39).

As indicated, Th17-high asthma is associated with neutrophilic airway inflammation. In a mouse model of acute exacerbation of chronic asthma, it was shown that although dexamethasone treatment suppressed airway inflammation associated with eosinophil and T-lymphocyte recruitment, it did not prevent the influx of neutrophils or the development of AHR, suggesting that Th17/neutrophilic inflammation is more resistant to dexamethasone treatment (79). Furthermore, in this model, dexamethasone inhibited histone acetyl transferase (HAT) activity in the lungs but failed to reverse the increased NF-κB activity and reduction of histone deacetylase-2 (HDAC2), which is one the mechanism of reduced ICS sensitivity (79).

The potential mechanisms underlying the effects of IL-17 on reduced steroid sensitivity have also been evaluated in vitro using human cells. Irvin C. et al (2014) found that Th2/Th17 cells in the bronchoalveolar lavage (BAL) from asthmatic patients which presented with higher IL-17 levels in the BAL, were resistant to dexamethasone-induced cell death. In addition, the expression level of MAP-ERK kinase 1 (MEK1), an inducer of AP-1, was elevated, suggesting its involvement in reduced ICS sensitivity (80).

In human airway epithelial cells, the ability of budesonide to inhibit TNF-α-induced IL-8 production was significantly reduced by IL-17A pretreatment (81), which could likely be attributed to enhanced phosphoinositide-3-kinase (PI3K) pathway activity and a subsequent reduced HDAC2 activity in response to IL-17A (81). Moreover, primary airway epithelial cells from asthmatics have been shown to express significantly higher levels of GRβ after IL-17A/F stimulation (82). These studies suggest that IL-17 might directly contribute to reduced ICS sensitivity of the airway epithelium.

Reduced ICS sensitivity has also been linked with high expression of GRβ. GRβ is an alternatively spliced form of GRs which binds to glucocorticoid receptor element (GRE) in the DNA but not with CS (76,83). Thus, it competes with GRα and acts as a negative regulator (76,83). Increased GRβ expression has been reported in peripheral blood mononuclear cells (PBMCs) in response to IL-17 exposure. This subsequently hindered dexamethasone-mediated prevention of cell proliferation and apoptosis, resulting in prolonged inflammation (84). mRNA expression profiles of PBMCs (mitogen-induced kinase phosphatase 1, IL-8, and GR-β) are considered relevant parameters to predict the response of clinical asthmatics to CS (85). Indeed, PBMCs isolated from ICS-unresponsive asthmatic patients secreted significantly higher levels of IL-17A when compared to those from steroid-responsive asthmatics, and IL-17A production was inversely correlated with the clinical response to prednisolone (86). Moreover, patients with a higher IL-17 gene signature exhibited a lower response to ICS therapy in FEV1%-predicted-over-30-months change (9).

Recent findings by Ouyang et al. (2020) suggest that colony stimulating factor 1 (CSF3), a key neutrophil survival cytokine, mediates an IL-17A/ICS synergistic interaction leading to increased airway neutrophilic inflammation. Thus, it was demonstrated that IL-17A and dexamethasone synergistically induced CSF3 gene expression in human ASM cells in vitro by increasing gene promoter activity and prevent CSF3 mRNA degradation (87). Targeting with anti-IL-17a or the small molecule IL-17 blocker cyanidin-3-glucoside (C3G) inhibited neutrophil influx into the airways in a steroid-insensitive neutrophil/Th17-high mouse model of acute asthma, underlining the significance of CSF3 in IL-17A-mediated reduction in ICS sensitivity (87).

**Targeting the IL-17 pathway in asthma**

The prevalence of heterogeneous phenotypes in severe asthma has become increasingly more evident, which makes cytokine-targeted therapies likely to be only beneficial in specific patient populations (88). In this review, we presented that IL-17 is upregulated in asthma, notably in severe asthma. Several preclinical and clinical studies reported relatively high level of IL-17, particularly IL-17A and IL-17F, in sputum, nasal and bronchial biopsies, and blood of severe asthma patients (11,12,14–16,19). Therefore, targeting IL-17/Th17 pathway may be a promising strategy, given its putative role in relevant processes in asthma, e.g., inflammation, airway remodeling, and AHR as has been discussed in this review. However, the current treatment for severe asthma, is focused predominantly on targeting Th2/eosinophilic inflammation, with sputum eosinophil counts and exhaled nitric oxide fraction (FENO) as a therapy guide, and therapies primarily targeting Th2 inflammation (e.g., IL-5, anti-IgE, anti-IL-4/IL-13) as treatment options (18). Furthermore, over the last decade, approximately 78% of all
randomized control trials (RCTs) on biologics under consideration for severe asthma have been targeted towards a Th2-high endotype (88).

Despite promising preclinical results that have been discussed in this review, clinical trials on IL-17 inhibition failed to demonstrate a sufficiently effective clinical response thus far. Brodalumab, a human anti-IL-17 receptor monoclonal antibody, did not meet its primary efficacy outcome (the asthma control questionnaire (ACQ)) in moderate to severe asthmatics treated with ICS (89). A significant improvement in ACQ was only observed in the high-reversibility patient subgroup (post-bronchodilator FEV1 improvement ≥ 20%; n = 112) (89). The study was well designed by anticipating the heterogeneity of the severe asthma population. Pre-specified subgroup analyses were done based on 9 different subgroups, based on bronchodilator reversibility, baseline FEV1% predicted, ACQ, ICS dose, FeNO level, peripheral eosinophils, sex, race, and weight (89). It should be noted that Th17-high inflammation (in which high anti-IL17 (Brodalumab) effects are expected) was not assessed in these patients. Moreover, the study populations were highly atopic (83% in total population; 79% and 84% in placebo and Brodalumab treatment arms, respectively). It has been reported that atopic asthma is more likely to correlate to an eosinophilic phenotype, therefore the subjects included in the study might not be the best target group for Brodalumab (90,91). IL-17-targeted therapy such as Brodalumab may be more beneficial in a specific Th17-high asthma subjects. Several endotyping and phenotyping strategies can be applied to define Th17-high asthma patients, namely TAC3 gene signatures, 6GS, and IL-17 gene signatures alongside airway inflammation phenotyping (eosinophilic, mixed, neutrophilic, and paucigranulocytic) as described previously in this review (7,9,35,38). Moreover, Brodalumab is proven effective in other IL-17-driven inflammatory diseases, i.e. psoriasis, rheumatoid arthritis, and psoriatic arthritis, indicating its potential in Th17-high asthma (92,93).

Phenotype-targeted clinical trials have been proven beneficial in evaluating biologic efficacies in asthma, but have not always been straightforward. Early anti-IL-5 monoclonal antibody (Mepolizumab) studies in asthmatics did not show significant results in asthma clinical measures (asthma exacerbations, AHR, FEV1, peak flow recordings) (94–96). Nevertheless, the levels of airway and peripheral eosinophil were greatly decreased with Mepolizumab (95,96). Only after the focus was shifted towards eosinophilic asthma patients the desired clinical effects of Mepolizumab on exacerbation frequency were found (97,98). Similar lessons to focus on the phenotype-specific subjects were learned from the development of other Th2-targeted asthma therapy, such as anti-IL-4R (Dupilumab) monoclonal antibody (mAb) (99,100). This advocates for the evaluation of IL17-targeted therapy in the Th17 high population. In addition, considering the significance of IL-17 in reduced ICS sensitivity, it will be important to also evaluate (oral) corticosteroid use and responsiveness as endpoints.

Another potential strategy in improving IL-17-targeted therapy in asthma is by antagonizing IL-17/IL-17 receptor interaction with small molecules instead of mAbs such as Brodalumab. The limitations of mAbs are their high cost, lack of oral bioavailability, and relatively large structures which make them difficult to be formulated as local delivery medications (i.e. inhalers) (101,102). Small molecule formulations instead of mAbs might circumvent some of these problems. Indeed, small molecules has potential to be developed into orally bioavailable drugs (103). A combined computational and hydrogen/deuterium exchange mass spectrometry (HDX-MS) study revealed an inhibitory small molecule binding site on IL-17A ligand called β-hairpin, that disrupted the interaction to its receptor (103). Recently, two small molecules (CBG040591 and CBG060392) targeting the interaction of IL-17A/IL-17RA were identified (101). Both molecules were biologically functional by preventing the production of IL-17A-induced CCL20 and CXCL8 in human keratinocytes. Moreover, molecule CBG060392 showed partial inhibition of IL-17A intracellular signaling, suggesting a functional downstream effect (101). In another computational study, Cyanidin, a natural small molecule compound, inhibited the IL-17A/IL-17RA interaction by docking into the IL-17RA pocket (104). Further, Cyanidin was shown to attenuated skin hyperplasia in murine psoriasis model, reduced inflammation in Th17-driven murine multiple sclerosis model, and alleviated AHR in murine obesity-induced and allergic asthma model (104). These findings encourage for exploration of other potential small molecules targeting IL-17/IL-17R.

Over the last 5 years, several preclinical studies revealed (novel) key factors/mechanisms involved in Th17/IL-17-driven airway inflammation and its effects on ICS responsiveness, which markedly improved our understanding of this complex pathway and will allow for more effective therapeutic targeting. Targeted interventions in humans so far have not been rewarding, but several innovative avenues for interventions are being explored. Also, in light of the high cost of research and developing therapies, it is important to identify which patients will most likely benefit from an approach specifically aimed at Th17/IL-17 inhibition, i.e., those patients presenting with a high IL-17 gene signature and Th2-low airway inflammation. Future research is also warranted to further explore the mechanisms underpinning the effects of the Th17/IL-17 pathway on ICS responsiveness to gain better insight in how to reverse reduced ICS sensitivity and ameliorate disease severity.
Chapter 4 - The pharmacological rationale for targeting IL-17 in asthma

The pharmacological rationale for targeting IL-17 in asthma

Funding
SFR received scholarship from lembaga pengelola dana pendidikan (LPDP) Indonesia.
SFR, AASD, MRG, and RG received a research funding from Sanofi Aventis Netherlands B.V.

Figure 2. Summary of IL-17 effects on asthma. A) IL-17 induced neutrophil chemokins production, e.g., CXCL1, CXCL2, CXCL5, GM-CSF, G-CSF, as well as TNF-α and IFN-γ resulting in increased neutrophil infiltration into the airway; B) IL-17 induces EMT, increases goblet cell hyperplasia, mucus and remodeling factor production in epithelial cells; IL-17 stimulates production of TGF-β, ECM deposition as well as transdifferentiation into mesenchymal phenotype in fibroblasts; IL-17 increases mesenchymal cell markers, promotes cell survival, migration and proliferation, and reduces cell apoptosis, resulting in increased ASM thickness. C) IL-17 triggers neutrophilic inflammation and AHR in vivo via increasing NF-κB, MEK1, PI3K activity, GR-β and CSF3/G-CSF expression, as well as reduction of HDAC2 activity. These effects might explain the linked between Th17-high inflammation and severe asthma. IL-17: interleukin 17; CXCL-: C-X-C ligand-; GM-CSF: granulocyte-macrophage colony-stimulating factor; G-CSF: granulocyte-colony stimulating factor; TNFα: tumor necrosis factor α; IFN-γ: interferon γ; EMT: epithelial to mesenchymal transition; TGF-β: transforming growth factor β; ECM: extracellular matrix; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; MEK1: MAP (Mitogen-Activated Protein) Kinase/ERK Kinase (Extracellular Signal-Regulated Kinase) Kinase 1; PI3K: phosphoinositide 3-kinase; GR-β: glucocorticoid receptor β; CSF3: colony stimulating factor 3; HDAC2: histone deacetylase 2. Created with BioRender.com.

Acknowledgments
We would like to thank Dedmer Schaafsma from Science Impact (Winnipeg, Canada) for post-editing the manuscript; and Lembaga pengelola dana pendidikan (LPDP) Indonesia for providing the scholarship for S.F.Rahmawati.

Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author Contributions
SFR, MTV, and RG conceived and designed the draft; SFR and MTV wrote the draft; HAMK ASSD MRG RG revised the draft.
Chapter 4 - The pharmacological rationale for targeting IL-17 in asthma

The pharmacological rationale for targeting IL-17 in asthma - Chapter 4

References


42. Willis CR, Siegel L, Mohn D, Esobar S, Wannberg S, et al. The pharmacological rationale for targeting IL-17 in asthma - Chapter 4 - The pharmacological rationale for targeting IL-17 in asthma - Chapter 4 - The pharmacological rationale for targeting IL-17 in asthma


Chapter 4 - The pharmacological rationale for targeting IL-17 in asthma


